Greg Harrison
Stock Analyst at B of A Securities
(4.61)
# 205
Out of 5,090 analysts
103
Total ratings
59.49%
Success rate
24.19%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $54 → $32 | $27.73 | +15.40% | 8 | Nov 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $9.61 | +212.17% | 3 | Oct 27, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $489.31 | -5.38% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $38.50 | +11.69% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $35.00 | -11.43% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $12.58 | +58.98% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $73.64 | -22.60% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $455.48 | -3.84% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $458.12 | -1.77% | 6 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.32 | +20.48% | 8 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $11 | $3.33 | +230.33% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $7.13 | +390.88% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $44.90 | +22.49% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $34.41 | +7.53% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $21.69 | +19.87% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $23.63 | -15.36% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.31 | +14.50% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $27.09 | +47.66% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $93.29 | -19.61% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $17.74 | +1.47% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $30.87 | -61.13% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.50 | +202.48% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.42 | +519.83% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $10.85 | -72.35% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $2.13 | +3,186.38% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $14.52 | +271.90% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $56.90 | +58.17% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Nov 20, 2025
Maintains: Buy
Price Target: $54 → $32
Current: $27.73
Upside: +15.40%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $9.61
Upside: +212.17%
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $489.31
Upside: -5.38%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $38.50
Upside: +11.69%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $35.00
Upside: -11.43%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $12.58
Upside: +58.98%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $73.64
Upside: -22.60%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $455.48
Upside: -3.84%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $458.12
Upside: -1.77%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.32
Upside: +20.48%
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $3.33
Upside: +230.33%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $7.13
Upside: +390.88%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $44.90
Upside: +22.49%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $34.41
Upside: +7.53%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $21.69
Upside: +19.87%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $23.63
Upside: -15.36%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.31
Upside: +14.50%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $27.09
Upside: +47.66%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $93.29
Upside: -19.61%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $17.74
Upside: +1.47%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $30.87
Upside: -61.13%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.50
Upside: +202.48%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.42
Upside: +519.83%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $10.85
Upside: -72.35%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $2.13
Upside: +3,186.38%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $14.52
Upside: +271.90%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $56.90
Upside: +58.17%